Pentosan Polysulfate

Pentosan polysulfate (PPS) is a semi‑synthetic sulfated polysaccharide that users most often try for interstitial cystitis relief—reported in 23 of 27 community notes with about a 65 % positive response—and, to a lesser extent, for joint health and osteoarthritis support, which appeared in 4 notes with a 100 % positive rate. In community reports the regimen is usually described as three times daily without a specified amount, whereas clinician guidance points to a fixed 100 mg per day given subcutaneously. Across the registered trial program, about a quarter of participants withdrew, highlighting the main tradeoff in the current evidence.

Half-life~20 h

Data last updated

ClinicalResearchDepthClinicalResearchEfficacyClinicalResearchSideEffectsAnecdotalEfficacyAnecdotalSideEffectsPriceno data3.71.34.53.13.2

Measured on 5 of 6 axes

Research Evidence

Evidence shape

Pentosan polysulfate sits in the moderate evidence tier, supported by human studies focused on treatment outcomes and diagnostic/mechanistic research. Across ten mapped indications, three sponsors have initiated eight registered trials, but only one completed trial has posted results and about a quarter of trials were withdrawn. Most indications remain thin or exploratory, with many relying on single trials or lacking any posted data, and two conditions show no trial activity at all.

Depthhow much
8 registered trials
3 completed · 1 with posted results · 3 recruiting / active · combined n=8
Breadthhow many areas
10 indications mapped
7 thin / exploratory · 1 animal-only · 6 single-trial long-tail
Qualityhow rigorous
Highest tier: Phase 3
3 distinct sponsors · 25% withdrawal rate · AE table from NCT02930005 · 1 linked publication on registered trials
Breadth and depth37 rows captured
Human
direct clinical signal
21
Animal
translational support
12
In vitro
mechanistic support
4
HighMediumLow

Anecdotal efficacy

Pentosan Polysulfate side effects

Clinical research side effects

Anecdotal side effects

Price

No live vendor pricing captured for this peptide yet.

Pentosan Polysulfate dosing & protocol

How Pentosan Polysulfate is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.

Research trials
Published clinical-trial protocols · n = 12
Typical dose
150 mg100 mg – 400 mg
typical
0
100 mg
200 mg
300 mg
400 mg
distribution of 4 reported doses · darker = more
Frequency
daily
Route
subQ

In the research trials, Pentosan Polysulfate was given subcutaneously at 150 mg daily (range 100–400 mg) or weight‑based at 10 mg/kg per day.

12 sources
Clinician practice
Doctor & published-protocol guidance
Typical dose
100 mg
typical
0
100 mg
200 mg
300 mg
400 mg
single reported dose
Frequency
daily
Route
subQ

Clinicians typically prescribe a fixed dose of 100 mg administered subcutaneously each day, with no reported cycling schedule in this tier.

Anecdotal
Community-reported real-world use
Typical dose
—
0
100 mg
200 mg
300 mg
400 mg
no dose captured for this tier yet
Frequency
unspecified

In community reports, the peptide was most often taken three times per day, though the specific amount was not stated in the majority of accounts.

Regulatory safety notes

Contraindications
  • • CONTRAINDICATIONS ELMIRON ® is contraindicated in
  • • patients with known hypersensitivity to the drug, structurally related compounds, or excipients.
Drug interactions
  • • Drug-Drug Interactions In a study in which healthy subjects received pentosan polysulfate sodium 100 mg capsule or placebo every 8 hours for 7 days, and were titrated with warfarin to an INR of 1.4 to 1.8, the pharmacokinetic parameters of R-warfarin and S-wa…

Related peptides

BPC-157TB-500WolverineKPVKLOWARA-290B7-33